![]() L-cysteine structure
|
Common Name | L-cysteine | ||
---|---|---|---|---|
CAS Number | 52-90-4 | Molecular Weight | 121.158 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 293.9±35.0 °C at 760 mmHg | |
Molecular Formula | C3H7NO2S | Melting Point | 220 °C (dec.)(lit.) | |
MSDS | Chinese USA | Flash Point | 131.5±25.9 °C |
Purity | Quantity | Budget | Inquiry |
---|
Use of L-cysteineL-Cysteine is a thiol-containing non-essential amino acid that is oxidized to form cystine. |
Name | L-cysteine |
---|---|
Synonym | More Synonyms |
Description | L-Cysteine is a thiol-containing non-essential amino acid that is oxidized to form cystine. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 293.9±35.0 °C at 760 mmHg |
Melting Point | 220 °C (dec.)(lit.) |
Molecular Formula | C3H7NO2S |
Molecular Weight | 121.158 |
Flash Point | 131.5±25.9 °C |
Exact Mass | 121.019745 |
PSA | 102.12000 |
LogP | 0.23 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.550 |
Water Solubility | 280 g/L (25 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
---|---|
Hazard Codes | Xn:Harmful |
Risk Phrases | R22;R36/37/38 |
Safety Phrases | S36-S37/39-S26 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | HA1600000 |
HS Code | 2930901000 |
~86% |
Literature: Arnold,L.D.; May,R.G.; Vederas,J.C. Journal of the American Chemical Society, 1988 , vol. 110, p. 2237 |
~92% |
Literature: HYPERBRANCH MEDICAL TECHNOLOGY, INC. Patent: WO2007/1926 A2, 2007 ; Location in patent: Page/Page column 257 ; |
~77% |
Literature: Beard, Timothy M; Turner, Nicholas J Chemical communications (Cambridge, England), 2002 , # 3 p. 246 - 247 |
HS Code | 2930909090 |
---|---|
Summary | 2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Drug Des. Devel. Ther. 9 , 1555-84, (2015) Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to current therapeutics. Alisertib (ALS, MLN823... |
|
The unique regulation of iron-sulfur cluster biogenesis in a Gram-positive bacterium.
Proc. Natl. Acad. Sci. U. S. A. 111(22) , E2251-60, (2014) Iron-sulfur clusters function as cofactors of a wide range of proteins, with diverse molecular roles in both prokaryotic and eukaryotic cells. Dedicated machineries assemble the clusters and deliver t... |
|
Pharmacological inhibition of dynamin II reduces constitutive protein secretion from primary human macrophages.
PLoS ONE 9(10) , e111186, (2014) Dynamins are fission proteins that mediate endocytic and exocytic membrane events and are pharmacological therapeutic targets. These studies investigate whether dynamin II regulates constitutive prote... |
Cysteine |
E 920 |
H-Cys-OH.Hcl |
CYSTEINE, L- |
H-Cys-OH |
L-2-Amino-3-mercaptopropionic acid |
CYSH |
L-Cysteine |
3-mercapto-L-Alanine |
L-Cys |
b-Mercaptoalanine |
Cys |
a-Amino-b-thiolpropionic Acid |
cystein |
(R)-(+)-Cysteine |
FEMA 3263 |
L-β-Mercaptoalanine |
EINECS 200-158-2 |
α-Amino-β-thiolpropionic acid, L- |
Thioserine |
(+)-2-Amino-3-mercaptopropionic acid |
α-Amino-β-mercaptopropanoic acid, L- |
(R)-2-amino-3-mercapto-Propanoic acid |
(2R)-2-amino-3-mercaptopropanoic acid |
(2R)-2-amino-3-sulfanylpropanoic acid |
hydrogen L-cysteinate |
β-Mercaptoalanine, L- |
(R)-2-Amino-3-mercaptopropionic acid |
(R)-Cysteine |
2-Amino-3-mercaptopropanoic acid, (R)- |
MFCD00064306 |
Acetylcysteine Impurity 2 |